Cargando…
Cycloserine did not increase depression incidence or severity at standard dosing for multidrug-resistant tuberculosis
In a longitudinal cohort of MDR-TB patients receiving individualised, DST-based treatment, neither the inclusion of cycloserine in a multidrug regimen nor the dose used (up to 750 mg daily) significantly increased incidence of depression during treatment https://bit.ly/3GtQmOH
Autores principales: | Tornheim, Jeffrey A., Udwadia, Zarir F., Arora, Prerna R., Gajjar, Ishita, Gupte, Nikhil, Sharma, Samridhi, Karane, Megha, Sawant, Namrata, Kharat, Nisha, Blum, Alexander J., Shivakumar, Shri Vijay Bala Yogendra, Mullerpattan, Jai B., Pinto, Lancelot M., Ashavaid, Tester F., Gupta, Amita, Rodrigues, Camilla |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8943271/ https://www.ncbi.nlm.nih.gov/pubmed/34949698 http://dx.doi.org/10.1183/13993003.02511-2021 |
Ejemplares similares
-
Increased Moxifloxacin Dosing Among Patients With Multidrug-Resistant Tuberculosis With Low-Level Resistance to Moxifloxacin Did Not Improve Treatment Outcomes in a Tertiary Care Center in Mumbai, India
por: Tornheim, Jeffrey A, et al.
Publicado: (2021) -
Effective use of telemedicine in Mumbai with a cohort of extensively drug-resistant “XDR” tuberculosis patients on bedaquiline during COVID-19 pandemic
por: Udwadia, Zarir F., et al.
Publicado: (2021) -
Pharmacokinetic analysis of linezolid for multidrug resistant tuberculosis at a tertiary care centre in Mumbai, India
por: Resendiz-Galvan, Juan Eduardo, et al.
Publicado: (2023) -
Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study
por: Migliori, Giovanni Battista, et al.
Publicado: (2021) -
Tropical pulmonary eosinophilia - A review
por: Mullerpattan, Jai B., et al.
Publicado: (2013)